Seal Rock Therapeutics is focused on developing innovative kinase inhibitors to address critical health issues related to organ injury, inflammation, and fibrosis, particularly in liver and central nervous system diseases. Their drug discovery platform leverages extensive experience in designing optimized kinase inhibitors, supported by computational chemistry, resulting in a diverse portfolio of over 400 unique compounds. These inhibitors exhibit various mechanisms of action and pharmacokinetic profiles, allowing for targeted treatment options, such as liver-selective and CNS-penetrant compounds. Notably, SRT-015, a second-generation ASK1 inhibitor, has shown promise in treating liver diseases with its unique trimodal therapeutic mechanism that addresses antifibrotic, anti-inflammatory, and anti-apoptotic activities.

In the realm of central nervous system diseases, Seal Rock is advancing SRT-055, a first-in-class dual LRRK2/ASK1 inhibitor aimed at treating conditions like Parkinson's disease. This compound targets the LRRK2 kinase, which is linked to genetic forms of Parkinson's, and addresses lysosomal dysfunction—a key pathology in the disease. By inhibiting both LRRK2 and ASK1, SRT-055 has the potential to enhance neuronal cell survival and reduce inflammation, offering a broader therapeutic approach for patients, including those with and without LRRK2 mutations. This dual inhibition strategy may lead to improved efficacy and a more comprehensive treatment option for a larger population of Parkinson's disease patients.

United States

Seal Rock Therapeutics, Inc. is discovering and developing small molecule inhibitors of ASK1 (apoptosis signal-regulating kinase 1), a protein that mediates apoptosis, inflammation, and fibrosis.  Seal Rock is currently focusing its efforts on hepatic indications including NASH (non-alcoholic steatohepatitis), a condition resulting from fatty liver disease, characterized by hepatic inflammation and cellular damage that lead to liver fibrosis.  Additional opportunities with ASK1 inhibitors include cardiac, immunological and neurodegenerative indications.

Seal Rock Therapeutics

Company Details